Ovarian Cancer

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in HRD-positive advanced ovarian cancer.

Thomas Herzog, MD, discusses the FDA approval of olaparib plus bevacizumab for the frontline maintenance treatment of patients with homologous recombination deficiency–positive ovarian cancer.

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses unanswered questions with PARP inhibitors in ovarian cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

R. Wendel Naumann, MD, discusses the FDA approval of niraparib in ovarian cancer and the impact on the current treatment paradigm.

Transformative clinical trials of PARP inhibitors have revolutionized the frontline treatment paradigm in advanced ovarian cancer.

Strategies with PARP inhibitors in ovarian cancer should focus on combination strategies to more effectively treat a heterogeneous patient population.

The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians.

The combination of the RAF-MEK inhibitor VS-6766 (CH5126766) and the FAK inhibitor defactinib (VS-6063) elicited early signals of clinical activity in a group of patients with KRAS-mutant advanced cancers.

Sharyn Lewin, MD, FACS, discusses the utility of hyperthermic intraperitoneal chemotherapy in newly diagnosed advanced-stage ovarian cancer.

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

David O'Malley, MD, discusses antitumor activity with veliparib in combination with chemotherapy in patients with high grade serous ovarian cancer.

An OncLive® Weekly Webinar Series highlighting best practices, treatment updates, and multidisciplinary approaches to ovarian cancer care through the COVID-19 pandemic. Join us Wednesday, June 3, 2020 at 8 PM EST.

In this third webinar of our series, we will take an in-depth look at systemic therapy and how the landscape of treatment continues to evolve during this time. Join us on Wednesday, May 20, 2020 at 8 PM EST.

An OncLive® Weekly Webinar Series highlighting best practices, treatment updates, and multidisciplinary approaches to ovarian cancer care through the COVID-19 pandemic. Join us Wednesday, May 13, 2020 at 8 PM EST.

The success of frontline maintenance niraparib in the phase III PRIMA trial extends to meeting biomarker-defined and other secondary endpoints and showing positive patient-reported outcomes.

David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.

Elizabeth M. Swisher, MD, discusses the implications of the phase III VELIA/GOG-3005 trial in ovarian cancer.

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.

The combination of olaparib and bevacizumab was found to improve progression-free survival outcomes versus bevacizumab alone as a frontline maintenance treatment in patients with newly diagnosed advanced high-grade serous ovarian cancer, regardless of the timing of surgery or residual disease status after surgery.

The combination of niraparib and bevacizumab as a frontline maintenance therapy was found to have impressive clinical activity in patients with advanced ovarian cancer who had a complete or partial response to frontline platinum-based chemotherapy plus bevacizumab.

Michelle M. Boisen, MD, discusses the scoring system for optimal debulking in ovarian cancer.

Casey M. Cosgrove, MD, discusses the utilization of PARP inhibition in ovarian cancer.

Trametinib monotherapy has emerged as a new treatment option for women with recurrent low-grade serous ovarian cancers based on improvements in survival outcomes and response rates demonstrated in a phase II/III study.